LEXX and LEXXW Related Headlines
Go Back- Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
- Lexaria Awarded New Patents
- Lexaria to Present at The LD Micro Invitational XIV
- Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
- Lexaria Bioscience (LEXX) Appoints Nelson Cabatuan as Chief Financial Officer
- Lexaria Bioscience (LEXX) Awards Contract For Next GLP-1 Human Pilot Study
- Lexaria Awards Contract For Next GLP-1 Human Pilot Study
- Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
- 7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
- Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
- Lexaria Bioscience (LEXX) Announces 1.56M Share Offering at $2.31/sh
- Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Lexaria Bioscience (LEXX) CEO Issues Letter to Shareholders
- Lexaria Releases Annual Letter from the CEO
- Lexaria Bioscience (LEXX) Unveils Planned 2024 GLP-1 Study Program
- Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
- Lexaria Bioscience (LEXX) Announces Investigational New Drug Application Filing Update
- Lexaria's Investigational New Drug Application Filing Update
- Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
- Lexaria (LEXX) Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
- Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
- Lexaria Bioscience (LEXX) Granted Two New Patents in Canada
- Lexaria Granted Two New Patents in Canada
- Lexaria Bioscience (LEXX) Prices 1.62M Share Offering at $0.97/sh
- Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
- Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
- Lexaria Bioscience (LEXX) Provides Update on Investigational New Drug Application Progress
- Lexaria Provides Update on Investigational New Drug Application Progress
- Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
- Lexaria Bioscience (LEXX) Plans Human Clinical Study with DehydraTECH-CBD
- Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
- Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
- Lexaria Bioscience (LEXX) Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
- Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
- Lexaria Bioscience (LEXX) Reports Publication of Research into DehydraTECH-CBD
- Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science
- Lexaria Bioscience (LEXX) Receives New Patents
- Lexaria Receives New Patents
- Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
- Lexaria Bioscience (LEXX) Appoints Mike Shankman as CFO
- Lexaria Appoints New Chief Financial Officer
- Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
- Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
- Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
- cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
- Lexaria Announces 2023 Annual Meeting Results
- Lexaria Bioscience (LEXX) Prices 2.1M Share Offering at $0.95/sh
- Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
- Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
LEXX and LEXXW Related Press Releases
Go Back- Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
- Lexaria Awarded New Patents
- Lexaria to Present at The LD Micro Invitational XIV
- Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
- Lexaria Awards Contract For Next GLP-1 Human Pilot Study
- Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
- 7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
- Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
- Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Lexaria Releases Annual Letter from the CEO
- Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
- Lexaria's Investigational New Drug Application Filing Update
- Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
- Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
- Lexaria Granted Two New Patents in Canada
- Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
- Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
- Lexaria Provides Update on Investigational New Drug Application Progress
- Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
- Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
- Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
- Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
- Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science
- Lexaria Receives New Patents
- Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
- Lexaria Appoints New Chief Financial Officer
- Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
- Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
- Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
- cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
- Lexaria Announces 2023 Annual Meeting Results
- Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
- Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
